VITAKEY, INC.
DURHAM, NC · CIK 0002079747 · Biotech · Private
Encapsulation technology platform for food ingredient delivery
vitakey.com →- Grants
- $2.4M
- 4 awards
- Sector median: 1
- Raised
- $44M
- 1 Form D · Aug 2025
- 14 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 0 granted · 40 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines | $295,924 | |
| Federal grant | Department of Health and Human Services · Phase I · Platform technology for targeted delivery of proteins to the intestines | $349,037 | |
| Federal grant | Department of Health and Human Services · Phase I · Platform technology for delivery of stabilized therapeutic microbes in powders with high water activity | $349,759 | |
| Private capital raised | Form D · SEC | $43,542,640 | |
| Federal grant | Department of Health and Human Services · Phase II · Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines | $1,437,278 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2017 | Homology Medicines | — | $107M |
| 2018 | Braveheart Bio | — | — |
| 2019 | Outer Biosciences, LLC | — | $4.0M |
| 2020 | VITAKEY, INC. | — | $44M |
| 2021 | SOMATOCEUTICS, LLC | — | — |
| 2022 | Enveda Therapeutics, Inc. | — | $67M |
| 2023 | Vigil Neuroscience | — | $195M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Anselmo AaronExecutive Officer
- Abigal BluntDirector
- Elaine ChaoDirector
- Roger FergusonDirector
- Ana JaklenecDirector
- Robert LangerDirector
- Matt MurrayExecutive Officer
- Catherine ReynoldsDirector · Executive Officer
- Wayne ReynoldsDirector
- Andrea StampExecutive Officer
Patents
- Heat-treated Extended-release Formulationsapplication
- Formulated Tastant Compositionsapplication
- Lipid Encapsulated Probiotic Compositionsapplication
- Nutraceutical Particlesapplication
- Heat-treated Extended-release Formulationsapplication
- Sprinkle Preparationsapplication
- Lipid Particle Formulations And Lipid Particle-fortified Beveragesapplication
- Microemulsion Particle Formulations And Microemulsion Particle-fortified Beveragesapplication
- Sprinkle Preparationsapplication
- Assessing Satietyapplication
- Compositions And Methods Of Controlling Mammalian Satietyapplication
- Sprinkle Preparationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.